Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
21 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05104268 | Study of a New Medical Device for Oral Mucositis(MDOM) | withdrawn | Early Phase 1 | 0 | E2Bio Life Sciences, LLCINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06402188 | ColoSeal™ ICD System Safety and Feasibility Studies(PROTECT I) | active not recruiting | N/A | 90 | Averto Medical, Inc.INDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT05876754 | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma(ProvIDHe) | active not recruiting | Phase 3 | 299 | Servier Affaires MédicalesINDUSTRY | 16 | Jul 31, 2026 | clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT05700149 | Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | recruiting | — | 300 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 15 | Jun 22, 2026 | clinicaltrials |
| NCT05872893 | Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone | completed | Phase 3 | 28 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05891821 | Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) | recruiting | Phase 2 | 20 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | active not recruiting | Phase 2 | 45 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632014 | CAYA Cancer Prospective Cohort Study | recruiting | — | 6,000 | Resonance, Inc.OTHER | 3 | Jun 8, 2026 | clinicaltrials |
| NCT05430971 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | recruiting | — | 200 | Immune Oncology Research InstituteOTHER | 15 | Jun 5, 2026 | clinicaltrials |
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | recruiting | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | recruiting | Phase 1 | 27 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT06715579 | Cardiac Angiosarcoma International Registry(CAIR) | recruiting | — | 500 | Immune Oncology Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07246213 | CAYA Cancer Retrospective Cohort Study | recruiting | — | 18,000 | Resonance, Inc.OTHER | 4 | Dec 19, 2025 | clinicaltrials |
| NCT05711992 | Rare Embryonal Tumors of the Central Nervous System: International Registry | recruiting | — | 300 | Immune Oncology Research InstituteOTHER | 9 | May 8, 2025 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC(YH001) | withdrawn | Phase 2 | 0 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT03390387 | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)(ALL-MB 2015) | unknown | N/A | 4,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT03072992 | "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer | completed | Phase 2 | 150 | National Center of Oncology, ArmeniaOTHER | 1 | Nov 27, 2019 | clinicaltrials |
Data updated 18 days agoSource updated unknownsource: clinicaltrials